These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35426173)

  • 1. A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine.
    Yu HJ; Thijssen E; van Brummelen E; van der Plas JL; Radanovic I; Moerland M; Hsieh E; Groeneveld GJ; Dodart JC
    Mov Disord; 2022 Jul; 37(7):1416-1424. PubMed ID: 35426173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
    Jankovic J; Goodman I; Safirstein B; Marmon TK; Schenk DB; Koller M; Zago W; Ness DK; Griffith SG; Grundman M; Soto J; Ostrowitzki S; Boess FG; Martin-Facklam M; Quinn JF; Isaacson SH; Omidvar O; Ellenbogen A; Kinney GG
    JAMA Neurol; 2018 Oct; 75(10):1206-1214. PubMed ID: 29913017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial.
    Eijsvogel P; Misra P; Concha-Marambio L; Boyd JD; Ding S; Fedor L; Hsieh YT; Sun YS; Vroom MM; Farris CM; Ma Y; de Kam ML; Radanovic I; Vissers MFJM; Mirski D; Shareghi G; Shahnawaz M; Singer W; Kremer P; Groeneveld GJ; Yu HJ; Dodart JC
    Nat Med; 2024 Jun; ():. PubMed ID: 38902546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.
    Brys M; Fanning L; Hung S; Ellenbogen A; Penner N; Yang M; Welch M; Koenig E; David E; Fox T; Makh S; Aldred J; Goodman I; Pepinsky B; Liu Y; Graham D; Weihofen A; Cedarbaum JM
    Mov Disord; 2019 Aug; 34(8):1154-1163. PubMed ID: 31211448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Phase I Trial of the α-Synuclein Antibody Lu AF82422.
    Buur L; Wiedemann J; Larsen F; Ben Alaya-Fourati F; Kallunki P; Ditlevsen DK; Sørensen MH; Meulien D
    Mov Disord; 2024 Jun; 39(6):936-944. PubMed ID: 38494847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.
    Volc D; Poewe W; Kutzelnigg A; Lührs P; Thun-Hohenstein C; Schneeberger A; Galabova G; Majbour N; Vaikath N; El-Agnaf O; Winter D; Mihailovska E; Mairhofer A; Schwenke C; Staffler G; Medori R
    Lancet Neurol; 2020 Jul; 19(7):591-600. PubMed ID: 32562684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study.
    Yu HJ; Dickson SP; Wang PN; Chiu MJ; Huang CC; Chang CC; Liu H; Hendrix SB; Dodart JC; Verma A; Wang CY; Cummings J
    EBioMedicine; 2023 Aug; 94():104665. PubMed ID: 37392597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy.
    Meissner WG; Traon AP; Foubert-Samier A; Galabova G; Galitzky M; Kutzelnigg A; Laurens B; Lührs P; Medori R; Péran P; Sabatini U; Vergnet S; Volc D; Poewe W; Schneeberger A; Staffler G; Rascol O;
    Mov Disord; 2020 Nov; 35(11):1957-1965. PubMed ID: 32882100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α-Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease.
    Smit JW; Basile P; Prato MK; Detalle L; Mathy FX; Schmidt A; Lalla M; Germani M; Domange C; Biere AL; Bani M; Carson S; Genius J
    Mov Disord; 2022 Oct; 37(10):2045-2056. PubMed ID: 35959805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers.
    Schenk DB; Koller M; Ness DK; Griffith SG; Grundman M; Zago W; Soto J; Atiee G; Ostrowitzki S; Kinney GG
    Mov Disord; 2017 Feb; 32(2):211-218. PubMed ID: 27886407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UB-311, a novel UBITh
    Wang CY; Wang PN; Chiu MJ; Finstad CL; Lin F; Lynn S; Tai YH; De Fang X; Zhao K; Hung CH; Tseng Y; Peng WJ; Wang J; Yu CC; Kuo BS; Frohna PA
    Alzheimers Dement (N Y); 2017 Jun; 3(2):262-272. PubMed ID: 29067332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal α-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort.
    Majbour NK; Abdi IY; Dakna M; Wicke T; Lang E; Ali Moussa HY; Thomas MA; Trenkwalder C; Safieh-Garabedian B; Tokuda T; Mollenhauer B; El-Agnaf O
    Mov Disord; 2021 Sep; 36(9):2048-2056. PubMed ID: 33978256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
    Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut.
    Nimmo JT; Smith H; Wang CY; Teeling JL; Nicoll JAR; Verma A; Dodart JC; Liu Z; Lin F; Carare RO
    Acta Neuropathol; 2022 Jan; 143(1):55-73. PubMed ID: 34741635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duodenal alpha-Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease.
    Emmi A; Sandre M; Russo FP; Tombesi G; Garrì F; Campagnolo M; Carecchio M; Biundo R; Spolverato G; Macchi V; Savarino E; Farinati F; Parchi P; Porzionato A; Bubacco L; De Caro R; Kovacs GG; Antonini A
    Mov Disord; 2023 May; 38(5):885-894. PubMed ID: 36847308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
    Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.
    Poewe W; Volc D; Seppi K; Medori R; Lührs P; Kutzelnigg A; Djamshidian A; Thun-Hohenstein C; Meissner WG; Rascol O; Schneeberger A; Staffler G; ; ; Poewe W; Seppi K; Djamshidian A; deMarzi R; Heim B; Mangesius S; Stolz R; Wachowicz K; Volc D; Thun-Hohenstein C; Riha C; Schneeberger A; Bürger V; Galabova G
    J Parkinsons Dis; 2021; 11(3):1079-1089. PubMed ID: 34092654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
    Clarke DK; Xu R; Matassov D; Latham TE; Ota-Setlik A; Gerardi CS; Luckay A; Witko SE; Hermida L; Higgins T; Tremblay M; Sciotto-Brown S; Chen T; Egan MA; Rusnak JM; Ward LA; Eldridge JH
    Lancet Infect Dis; 2020 Apr; 20(4):455-466. PubMed ID: 31952923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.